| Product Unit Size | Cost | Quantity | Stock |
|---|
CYC-116 inhibits aurora kinases A and B (AurA, AurB), preventing mitotic spindle formation and proper completion of mitosis. This compound exhibits anticancer chemotherapeutic activity and is currently in clinical trials. CYC-116 inhibits proliferation of a variety of cancer cells.
| Cas No. | 693228-63-6 |
|---|---|
| Purity | ≥98% |
| Formula | C18H20N6OS |
| Formula Wt. | 368.46 |
| IUPAC Name | 4-methyl-5-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine |
| Solubility | DMSO 24 mg/mL warmed (65.13 mM) Water Insoluble Ethanol Insoluble |
| Appearance | Yellow Powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Kamei H, Jackson RC, Zheleva D, et al. An integrated pharmacokinetic-pharmacodynamic model for an Aurora kinase inhibitor. J Pharmacokinet Pharmacodyn. 2010 Aug;37(4):407-34. PMID: 20694801.
Wang S, Midgley CA, Scaërou F, et al. Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors. J Med Chem. 2010 Jun 10;53(11):4367-78. PMID: 20462263.